Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / FTSV - Trillium Therapeutics: Investors To See Further Upside Via CD47 Focus

FTSV - Trillium Therapeutics: Investors To See Further Upside Via CD47 Focus

Forty Seven Inc.
  • Trillium Therapeutics has an encouraging pipeline with key differentiators that have attracted recent investor interest.
  • The 2 major candidates, TTI-621 & 622 have shown monotherapy activity in a breadth of haematologic cancers as CD47 targeting drugs.
  • Shares have rallied over 4700% over the single-year period, where further upside is imminent on the back of key upcoming catalysts.
  • We see a fair value range of $17.50 to ~$27, and believe the market will continue to reward the company as they continue moving towards converting the pipeline.

For further details see:

Trillium Therapeutics: Investors To See Further Upside Via CD47 Focus
Stock Information
Company Name: Forty Seven Inc.
Stock Symbol: FTSV
Market: NASDAQ
Website: fortyseveninc.com
Menu
FTSV FTSV Quote FTSV Short FTSV News FTSV Articles FTSV Message Board
Get FTSV Alerts

News, Short Squeeze, Breakout and More Instantly...